The rapid development of AI has resulted in an unprecedented paradigm shift across various industries, with aerospace among the laureates of this transformation. This review paper attempts to explore and provide comprehensive overview of the aerospace research imperatives from the AI perspective, detailing the technical sides of the full lifecycle from vehicle design and operational optimisation to advanced air traffic management systems. By examining real-world engineering implementations, the review demonstrates how AI-driven solutions are directly addressing longstanding challenges in aerospace, such as optimising flight performance, reducing operational costs and improving system reliability. A significant emphasis is placed on the crucial roles of AI in health monitoring and predictive maintenance, areas that are pivotal for ensuring the safety and longevity of aerospace endeavors, and which are now increasingly adopted in industry for remaining useful life (RUL) forecasting and condition-based maintenance strategies. The paper also discusses AI embedded in quality control and inspection processes, where it boosts accuracy, efficiency and fault detection capability. The review provides insight into the state-of-the-art applications of AI in planetary exploration, particularly within the realms of autonomous scientific instrumentation and robotic prospecting, as well as surface operations on extraterrestrial bodies. An important case study is India’s Chandrayaan-3 mission, demonstrating the application of AI in both autonomous navigation and scientific exploration within the challenging environments of space. By furnishing an overview of the field, the paper frames the ever-important, increasing domains of AI as the forefront in the advancement of aerospace engineering and opens avenues for further discussion regarding the limitless possibilities at the juncture of intelligent systems and aerospace innovation.

Malacological surveys were conducted in 2021 in the Kimpese region of Central Kongo Province, west of the Democratic Republic of Congo (DRC). Snail specimens were collected following a standardised protocol, identified using morphological and molecular methods, and tested for schistosome infection using a diagnostic PCR assay. Positive snail samples were sequenced to characterise the infecting schistosome species. Partial mitochondrial cytochrome c oxidase subunit 1 (COX1) gene sequences were used in phylogenetic analyses to explore the evolutionary position of these snail species within the broader African context. At least four intermediate snail hosts were identified: Bulinus truncatus, Bulinus forskalii, Biomphalaria pfeifferi, and a Biomphalaria species belonging to the Nilotic species complex (tentatively named Biomphalaria cf sudanica), of which the species identity needs to be confirmed. A total of 37 out of 1,196 snails (3.1%) tested positive for schistosome infection, with an infection prevalence of 7.4% for B. truncatus with Schistosoma haematobium and 1.5% for Biomphalaria spp. with Schistosoma mansoni. The S. mansoni sequence retrieved from these samples formed a basal clade relative to Zambian isolates, whereas S. haematobium grouped with the most frequently characterised haplotype cluster previously identified across mainland Africa. It is important to note that no animal schistosome species were identified in this study. Both the sequences from the snail hosts and the parasites represent novel contributions from the DRC. Additionally, the findings update the current knowledge of schistosomiasis transmission in the Kimpese region by providing insight into the phylogenetic placement, species diversity, and infection status of local snail populations.

Depth-averaged systems of equations describing the motion of fluid–sediment mixtures have been widely adopted by scientists in pursuit of models that can predict the paths of dangerous overland flows of debris. As models have become increasingly sophisticated, many have been developed from a multi-phase perspective in which separate, but mutually coupled sets of equations govern the evolution of different components of the mixture. However, this creates the opportunity for the existence of pathological instabilities stemming from resonant interactions between the phases. With reference to the most popular approaches, analyses of two- and three-phase models are performed, which demonstrate that they are more often than not ill posed as initial-value problems over physically relevant parameter regimes – an issue which renders them unsuitable for scientific applications. Additionally, a general framework for detecting ill posedness in models with any number of phases is developed. This is used to show that small diffusive terms in the equations for momentum transport, which are sometimes neglected, can reliably eliminate this issue. Conditions are derived for the regularisation of models in this way, but they are typically not met by multi-phase models that feature diffusive terms.

During nematode surveys conducted to investigate the biodiversity of plant-parasitic nematodes in Mediterranean olive groves with different management strategies (organic and conventional), a nematode population of the genus Neothada was detected in southern Spain. Application of integrative taxonomical approaches clearly demonstrated that it is a new species described herein as Neothada olearum sp. nov., also representing the first report of the genus in Spain. The new species is amphimictic, characterised by a short body (563–774 μm); cuticle widely annulated (2.5–3.0 μm); total number of body annuli 214–226; 16 longitudinal ridges giving a tessellate body surface; stylet without distinct basal knobs (9.0–11.0 μm); and tail elongate-conoid, with tip bluntly rounded. The results of molecular analysis of D2-D3 28S rRNA, ITS rRNA, partial 18S rRNA, and cytochrome oxidase c subunit 1 (COI) gene sequences support for the new species status and clearly separated from N. major and other species within Neothada. Phylogenetic analyses of ribosomal and mitochondrial markers of this study suggested that Neothada is a monophyletic genus, clearly separated from Thada.

Background: While efgartigimod usage is expected to reduce immunoglobulin (IG) utilization, evidence in clinical practice is limited. Methods: In this retrospective cohort study, patients with gMG treated with efgartigimod for ≥1-year were identified from US medical/pharmacy claims data (April 2016-January 2024) and data from the My VYVGART Path patient support program (PSP). The number of IG courses during 1-year before and after efgartigimod initiation (index date) were evaluated. Patients with ≥6 annual IG courses were considered chronic IG users. Myasthenia Gravis Activities of Daily Living (MG-ADL) scores before and after index were obtained from the PSP where available. Descriptive statistics were used without adjustment for covariates. Results: 167 patients with ≥1 IG claim before index were included. Prior to efgartigimod initiation, the majority of patients (62%) received IG chronically. During the 1-year after index, the number of IG courses fell by 95% (pre: 1531, post: 75). 89% (n=149/167) of patients fully discontinued IG usage. Mean (SD) best-follow up MG-ADL scores were significantly reduced after index (8.0 [4.1] to 2.8 [2.1], P<0.05, n=73/167, 44%). Conclusions: Based on US claims, IG utilization was substantially reduced among patients who continued efgartigimod for ≥1-year, with patients demonstrating a favorable MG-ADL response.

Background: TERT promoter mutation (TPM) is an established biomarker in meningiomas associated with aberrant TERT expression and reduced progression-free survival (PFS). TERT expression, however, has also been observed even in tumours with wildtype TERT promoters (TP-WT). This study aimed to examine TERT expression and clinical outcomes in meningiomas. Methods: TERT expression, TPM status, and TERT promoter methylation of a multi-institutional cohort of meningiomas (n=1241) was assessed through nulk RNA sequencing (n=604), Sanger sequencing of the promoter (n=1095), and methylation profiling (n=1218). 380 Toronto meningiomas were used for discovery, and 861 external institution samples were compiled as a validation cohort. Results: Both TPMs and TERTpromoter methylation were associated with increased TERT expression and may represent independent mechanisms of TERT reactivation. TERT expression was detected in 30.4% of meningiomas that lacked TPMs, was associated with higher WHO grades, and corresponded to shorter PFS, independent of grade and even among TP-WT tumours. TERT expression was associated with a shorter PFS equivalent to those of TERT-negative meningiomas of one higher grade. Conclusions: Our findings highlight the prognostic significance of TERT expression in meningiomas, even in the absence of TPMs. Its presence may identify patients who may progress earlier and should be considered in risk stratification models.

Background: The WHO grade of meningioma was updated in 2021 to include homozygous deletions of CDKN2A/B and TERT promotor mutations. Previous work including the recent cIMPACT-NOW statement have discussed the potential value of including chromosomal copy number alterations to help refine the current grading system. Methods: Chromosomal copy number profiles were inferred from from 1964 meningiomas using DNA methylation. Regularized Cox regresssion was used to identify CNAs independenly associated with post-surgical and post-RT PFS. Outcomes were stratified by WHO grade and novel CNAs to assess their potential value in WHO critiera. Results: Patients with WHO grade 1 tumours and chromosome 1p loss had similar outcomes to those with WHO grade 2 tumours (median PFS 5.83 [95% CI 4.36-Inf] vs 4.48 [4.09-5.18] years). Those with chromosome 1p loss and 1q gain had similar outcomes to those with WHO grade 3 cases regardless of initial grade (median PFS 2.23 [1.28-Inf] years WHO grade 1, 1.90 [1.23-2.25] years WHO grade 2, compared to 2.27 [1.68-3.05] years in WHO grade 3 cases overall). Conclusions: We advocate for chromosome 1p loss being added as a criterion for a CNS WHO grade of 2 meningioma and addition of 1q gain as a criterion for a CNS WHO grade of 3.

Background: Neck vessel imaging is often performed in hyperacute stroke to allow neurointerventionalists to estimate access complexity. This study aimed to assess clinician agreement on catheterization strategies based on imaging in these scenarios. Methods: An electronic portfolio of 60 patients with acute ischemic stroke was sent to 53 clinicians. Respondents were asked: (1) the difficulty of catheterization through femoral access with a regular Vertebral catheter, (2) whether to use a Simmons or reverse-curve catheter initially, and (3) whether to consider an alternative access site. Agreement was assessed using Fleiss’ Kappa statistics. Results: Twenty-two respondents (7 neurologists, 15 neuroradiologists) completed the survey. Overall there was slight interrater agreement (κ=0.17, 95% CI: 0.10–0.25). Clinicians with >50 cases annually had better agreement (κ=0.22) for all questions than those with fewer cases (κ=0.07). Agreement did not significantly differ by imaging modality: CTA (κ=0.18) and MRA (κ=0.14). In 40/59 cases (67.80%), at least 25% of clinicians disagreed on whether to use a Simmons or reverse-curve catheter initially. Conclusions: Agreement on catheterization strategies remains fair at best. Our results suggest that visual assessment of pre-procedural vessels imaging is not reliable for the estimation of endovascular access complexity.

Background: Late-onset Pompe disease (LOPD) is caused by a deficiency of acid α-glucosidase (GAA), leading to progressive muscle and respiratory decline. Cipaglucosidase alfa (cipa), a recombinant human GAA naturally enriched with bis-mannose-6-phosphate, exhibits improved muscle uptake but is limited by inactivation at near-neutral blood pH. Miglustat (mig), an enzyme stabiliser, binds competitively and reversibly to cipa, enhancing its stability and activity. Methods: In dose-finding studies, Gaa-/- mice were treated with cipa (20 mg/kg) +/- mig (10 mg/kg; equivalent human dose ~260 mg). Clinical study methodologies have been published (Schoser et al. Lancet Neurol 2021:20;1027–37; Schoser et al. J Neurol 2024:271;2810–23). Results: In Gaa-/- mice, cipa+mig improved muscle glycogen reduction more than cipa alone and grip strength to levels approaching wild-type mice. LOPD patients (n=11) treated with cipa alone showed dose-dependent decreases in hexose tetrasaccharide (Hex4) levels by ~15% from baseline, decreasing another ~10% with added mig (260 mg). In a head-to-head study, cipa+mig had a similar safety profile to alglucosidase alfa. Among 151 patients (three trials), mig-related adverse events occurred in 21 (13.9%), none serious. Conclusions: Mig stabilised cipa in circulation, improving cipa exposure, further reducing Hex4 levels and was well tolerated in clinical studies in patients with LOPD. Sponsored by Amicus Therapeutics, Inc.

Background: Plasma pTau217 is a robust biomarker for the diagnosis of Alzheimer’s disease (AD). However, most pTau217 assays are not widely available for clinical testing. We assessed the performance of two commercially available plasma pTau217 immunoassays in a clinical diagnostic laboratory for AD diagnosis. Methods: 219 plasma samples from healthy controls with negative amyloid PET, 115 plasma samples from pathology-confirmed and 263 samples with confirmed amyloid PET were selected. Plasma pTau217 levels were measured using the ALZpath pTau217 assay on the Quanterix HD-X Simoa platform and the Lumipulse pTau217 assay on the Lumipulse G1200 platform at and BC Neuroimmunology Lab and Neurocode USA. Results: For the ALZpath assay, the coefficients were 10.4%, 10.4%, and 9.9%, and for the Fujirebio assay, were 12.1%, 12.2%, and 5.3%, respectively. Sample stability and interference were similar between the two assays, although moderate heterophilic antibody interference and reduced frozen sample stability at -20˚C were observed for the Fujirebio assay. Both assays demonstrated similar clinical performance and differentiated individuals with AD (ALZpath AUC = 0.94; Fujirebio AUC = 0.90). Conclusions: The performance of the two pTau 217 assays was comparable. The clinical separation between the healthy controls and those with Amyloid pathology was nearly complete for both assays.

Multicenter clinical trials are essential for evaluating interventions but often face significant challenges in study design, site coordination, participant recruitment, and regulatory compliance. To address these issues, the National Institutes of Health’s National Center for Advancing Translational Sciences established the Trial Innovation Network (TIN). The TIN offers a scientific consultation process, providing access to clinical trial and disease experts who provide input and recommendations throughout the trial’s duration, at no cost to investigators. This approach aims to improve trial design, accelerate implementation, foster interdisciplinary teamwork, and spur innovations that enhance multicenter trial quality and efficiency. The TIN leverages resources of the Clinical and Translational Science Awards (CTSA) program, complementing local capabilities at the investigator’s institution. The Initial Consultation process focuses on the study’s scientific premise, design, site development, recruitment and retention strategies, funding feasibility, and other support areas. As of 6/1/2024, the TIN has provided 431 Initial Consultations to increase efficiency and accelerate trial implementation by delivering customized support and tailored recommendations. Across a range of clinical trials, the TIN has developed standardized, streamlined, and adaptable processes. We describe these processes, provide operational metrics, and include a set of lessons learned for consideration by other trial support and innovation networks.

Determining the factors that impact the risk for infection with SARS-CoV-2 is a priority as the virus continues to infect people worldwide. The objective was to determine the effectiveness of vaccines and other factors associated with infection among Canadian healthcare workers (HCWs) followed from 15 June 2020 to 1 December 2023. We also investigate the association between antibodies to SARS-CoV-2 and subsequent infections with SARS-CoV-2. Of the 2474 eligible participants, 2133 (86%) were female, 33% were nurses, the median age was 41 years, and 99.3% had received at least two doses of COVID-19 vaccine by 31 December 2021. The incidence of SARS-CoV-2 was 0.91 per 1000 person-days. Prior to the circulation of the Omicron variants, vaccine effectiveness (VE) was estimated at 85% (95% CI 1, 98) for participants who received the primary series of vaccine. During the Omicron period, relative adjusted VE was 43% (95% CI 29, 54), 56% (95% CI 42, 67), and 46% (95% CI 24, 62) for 3, 4, and ≥ 5 doses compared with those who received primary series after adjusting for previous infection and other covariates. Exposure to infected household members, coworkers, or friends in the previous 14 days were risk factor for infection, while contact with an infected patient was not statistically significant. Participants with higher levels of immunoglobulin G (IgG) anti-receptor binding domain (RBD) antibodies had lower rates of infection than those with the lowest levels. COVID-19 vaccines remained effective throughout the follow-up of this cohort of highly vaccinated HCWs. IgG anti-RBD antibody levels may be useful as correlates of protection for issues such as vaccine development and testing. There remains a need to increase the awareness among HCWs about the risk of contracting SARS-CoV-2 from contacts at a variety of venues.

Distinguishing early domesticates from their wild progenitors presents a significant obstacle for understanding human-mediated effects in the past. The origin of dogs is particularly controversial because potential early dog remains often lack corroborating evidence that can provide secure links between proposed dog remains and human activity. The Tumat Puppies, two permafrost-preserved Late Pleistocene canids, have been hypothesized to have been littermates and early domesticates due to a physical association with putatively butchered mammoth bones. Through a combination of osteometry, stable isotope analysis, plant macrofossil analysis, and genomic and metagenomic analyses, this study exploits the unique properties of the naturally mummified Tumat Puppies to examine their familial relationship and to determine whether dietary information links them to human activities. The multifaceted analysis reveals that the 14,965–14,046 cal yr BP Tumat Puppies were littermates who inhabited a dry and relatively mild environment with heterogeneous vegetation and consumed a diverse diet, including woolly rhinoceros in their final days. However, because there is no evidence of mammoth consumption, these data do not establish a link between the canids and ancient humans.

The Australian SKA Pathfinder (ASKAP) offers powerful new capabilities for studying the polarised and magnetised Universe at radio wavelengths. In this paper, we introduce the Polarisation Sky Survey of the Universe’s Magnetism (POSSUM), a groundbreaking survey with three primary objectives: (1) to create a comprehensive Faraday rotation measure (RM) grid of up to one million compact extragalactic sources across the southern $\sim50$% of the sky (20,630 deg$^2$); (2) to map the intrinsic polarisation and RM properties of a wide range of discrete extragalactic and Galactic objects over the same area; and (3) to contribute interferometric data with excellent surface brightness sensitivity, which can be combined with single-dish data to study the diffuse Galactic interstellar medium. Observations for the full POSSUM survey commenced in May 2023 and are expected to conclude by mid-2028. POSSUM will achieve an RM grid density of around 30–50 RMs per square degree with a median measurement uncertainty of $\sim$1 rad m$^{-2}$. The survey operates primarily over a frequency range of 800–1088 MHz, with an angular resolution of 20” and a typical RMS sensitivity in Stokes Q or U of 18 $\mu$Jy beam$^{-1}$. Additionally, the survey will be supplemented by similar observations covering 1296–1440 MHz over 38% of the sky. POSSUM will enable the discovery and detailed investigation of magnetised phenomena in a wide range of cosmic environments, including the intergalactic medium and cosmic web, galaxy clusters and groups, active galactic nuclei and radio galaxies, the Magellanic System and other nearby galaxies, galaxy halos and the circumgalactic medium, and the magnetic structure of the Milky Way across a very wide range of scales, as well as the interplay between these components. This paper reviews the current science case developed by the POSSUM Collaboration and provides an overview of POSSUM’s observations, data processing, outputs, and its complementarity with other radio and multi-wavelength surveys, including future work with the SKA.

Higher-quality Australian diets are reported to taste more bitter(1), have healthier nutritional profiles and align more closely with the recommendations of the Australian Dietary Guidelines(2). Greater consumption of bitter foods may benefit health, but most research has focused on green leafy vegetables(3). However, there are other foods and beverages (F&Bs) that taste bitter and could increase the bitterness of diets if consumed in greater amounts(2). Yet, strategies to increase bitter F&B consumption and enhance the bitterness of diets remain largely underexplored. An online-based cross-sectional survey of Australian adults was conducted (in July and August 2023) to explore barriers, facilitators, and strategies associated with willingness to try or increase consumption of bitter F&Bs. Eight non-discretionary bitter F&Bs available in the Australian market (including coffee, tea, soda water, Brussels sprouts, rockets, grapefruit, walnuts, and eggplant) were selected. The design of survey questions was guided by conceptual models of food choice. Respondents were asked about their familiarity with and consumption habits of bitter F&Bs and their willingness to incorporate more bitter F&Bs into their diets. Respondents were grouped into those who had never tried bitter F&Bs, non-consumers or consumers, who were further categorised into low-, moderate- or high-consumers. This analysis focused on respondents with low bitter F&B consumption, non-consumers, and individuals who had never tried bitter F&Bs, as the potential to increase consumption was greatest. This study enrolled 879 respondents across Australia. Respondents had previously tried an average of six of the eight bitter F&Bs (median = 6). Most respondents (85.4%) were willing to increase their consumption of bitter F&Bs. While the bitter taste was consistently reported as the main barrier to greater consumption, the reported facilitators and strategies varied between consumer groups and the different F&Bs. More than half of the respondents (61.1%) had never tried bitter vegetables (i.e., Brussels sprouts and rockets). For this group, ‘nutrition education’ (selected by 34%) and ‘appealing presentation’ (selected by 25.9%) were the most commonly selected facilitator and preferred strategy, respectively. Non-consumers of other bitter foods in the survey reported ‘price’ (selected by 43.8%) and ‘convenience’ (selected by 16.5%) as the most important facilitator and strategy, respectively. While ‘food availability’ (selected by 39.3%) was the common facilitator among low-consumers of bitter beverages, ‘easier preparation’ and ‘altering the taste’ (selected by 19.9% and 17.3%) were the most preferred strategies. This study provides valuable insights into the acceptability of bitter F&Bs among Australian adults. These findings could help tailor dietary interventions to groups of individuals based on their consumption habits of particular bitter F&Bs to support increased consumption. Further research is needed to understand whether improving bitter F&B consumption increases the bitterness of diets overall and whether this is associated with improved health outcomes.